For your adult patients with
With Reblozyl—the first and only erythroid maturation
agent—you can reduce patients’ red blood cell (RBC) transfusion burden.1-4
Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia associated with beta-thalassemia.1
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See Section 4.8 in the EU Summary of Product Characteristics for more information. Before prescribing Reblozyl, please refer to the EU Summary of Product Characteristics.